We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

100 hedge funds and large institutions have $745M invested in 4D Molecular Therapeutics in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 19

43% more capital invested

Capital invested by funds: $522M → $745M (+$223M)

38% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 16

6.97% more ownership

Funds ownership: 91.5% → 98.47% (+7%)

6% more funds holding

Funds holding: 94 → 100 (+6)

31% less call options, than puts

Call options by funds: $1.3M | Put options by funds: $1.89M

Holders
100
Holders Change
+6
Holders Change %
+6.38%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
48
Reduced
19
Closed
16
Calls
$1.3M
Puts
$1.89M
Net Calls
-$595K
Net Calls Change
+$153K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$56.5M
2
VA
VR Adviser
New York
+$55.2M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$17.7M
4
Viking Global Investors
Viking Global Investors
Connecticut
+$15.6M
5
DM
Deerfield Management
New York
+$12M

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$8.59M
2
Norges Bank
Norges Bank
Norway
-$5.05M
3
SCM
Soleus Capital Management
Connecticut
-$4.61M
4
Morgan Stanley
Morgan Stanley
New York
-$3.21M
5
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$2.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
PWM
26
Perigon Wealth Management
California
$4.45M – – –
OM
27
Opaleye Management
Massachusetts
$4.01M -$1.7M -92,300 -29%
SCM
28
Soleus Capital Management
Connecticut
$3.96M -$4.61M -250,252 -53%
Invesco
29
Invesco
Georgia
$3.9M +$3.97M +215,576 New
Rafferty Asset Management
30
Rafferty Asset Management
New York
$3.56M +$1.15M +62,367 +46%
Goldman Sachs
31
Goldman Sachs
New York
$3.51M -$65.1K -3,537 -2%
Two Sigma Investments
32
Two Sigma Investments
New York
$3.35M -$290K -15,744 -8%
CS
33
Candriam SCA
Luxembourg
$3.13M -$1.14M -62,000 -26%
Wellington Management Group
34
Wellington Management Group
Massachusetts
$3.06M -$118K -6,432 -4%
First Manhattan
35
First Manhattan
New York
$2.61M +$2.66M +144,492 New
Barclays
36
Barclays
United Kingdom
$2.57M +$1.57M +85,235 +149%
Voloridge Investment Management
37
Voloridge Investment Management
Florida
$2.45M +$434K +23,563 +21%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$2.1M +$144K +7,822 +7%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$2.03M +$227K +12,346 +12%
Bank of America
40
Bank of America
North Carolina
$1.85M -$1.66M -90,375 -47%
N
41
Nuveen
North Carolina
$1.76M -$1.09M -59,311 -38%
AllianceBernstein
42
AllianceBernstein
Tennessee
$1.6M +$1.32M +71,540 +418%
Verition Fund Management
43
Verition Fund Management
Connecticut
$1.31M +$1.34M +72,709 New
EC
44
EcoR1 Capital
California
$1.21M +$1.23M +66,978 New
Swiss National Bank
45
Swiss National Bank
Switzerland
$1.11M +$425K +23,100 +60%
Citigroup
46
Citigroup
New York
$1.05M -$985K -53,521 -48%
UBS Group
47
UBS Group
Switzerland
$973K +$26.7K +1,451 +3%
Blackstone Inc
48
Blackstone Inc
New York
$904K +$921K +50,000 New
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$885K +$27.4K +1,487 +3%
BG
50
Bellevue Group
Switzerland
$813K +$828K +45,000 New
1
2
3 4 5

FDMT Hedge Fund Activity: Q2 2023 in Review

100 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q2 2023, worth a combined $745M — up 43% from $522M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new FDMT positions and 16 closed out — a net gain of 6 holders — while 48 added to existing stakes and 19 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $56.5M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $8.59M sold.

  • 100 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q2 2023, up from 94 in Q1 2023.
  • Funds reported $745M of 4D Molecular Therapeutics stock for Q2 2023, up 43% quarter-over-quarter.
  • 22 funds opened new 4D Molecular Therapeutics positions in Q2 2023 and 16 closed out, a net change of +6 holders.
  • The largest 4D Molecular Therapeutics buyer in Q2 2023 was RA Capital Management, an estimated $56.5M added.
  • The largest 4D Molecular Therapeutics seller in Q2 2023 was Octagon Capital Advisors, an estimated $8.59M sold.

Based on aggregated 13F filings for Q2 2023.